This book is Edited by: Atta-ur-Rahman, Published on: February 26, 2019.
The fourth volume of the series continues to bring forth informative volumes on the multi-disciplinary aspects of the clinical treatment of HIV.
The book series is edited by Dr. Atta-ur-Rahman and brings forth five reviews written by contributors from different institutions around the world, including USA, Brazil, South Africa and China. Readers will find in this volume a discussion of the design and synthesis of HIV-1 protease inhibitors based on a cyclic sulfonamide core structure, magnetic nanocarriers for delivering therapeutics which can exert changes at genetic levels to treat AIDS, the development of integrase inhibitor drugs and other HIV drugs developed through flow technology that are approved by the FDA, the development and clinical progress on chemokine receptor-based HIV entry inhibitors, and finally a review of the most common co-infections found in HIV carriers (epidemiology, clinical features and evidence-based treatments).
The volume is essential reading for pharmacologists and clinicians involved in pre-clinical and clinical research of HIV / AIDS medication and therapy.
About the Author:
Prof. Dr. Atta-ur-Rahman
Prof. Dr. Atta-ur-Rahman, Ph.D. in organic chemistry from Cambridge University (1968), has over 1080 international publications in several fields of organic chemistry including 751 research publications, 37 international patents, 69 chapters in books and 222 books published largely by major U.S. and European presses. He is the Editor-in-Chief of eight European Chemistry journals. He is Editor of the world's leading encyclopedic series of volumes on natural products, Studies in Natural Product Chemistry, 54 volumes of which have been published under his Editorship by Elsevier during the last two decades.
Keywords: HIV, AIDS, Virology, HIV-1 Protease Inhibitors, HIV Medicine, Retrovirus, HAART, Antiretroviral Therapy, Magnetic Nanotherapeutics, neuroAIDS, Chemokine Receptor-Based HIV Entry Inhibitors, reverse transcriptase inhibitors, HIV-1 protease inhibitors, HIV prevention, Integrase Inhibitor, Sexually Co-infections, HIV-1 Replication Blocking, antiretroviral resistance, antiretroviral efficacy, Antiretroviral drugs.